Preserving fertility during cancer treatments
Cancer treatment — and cancer itself — can threaten fertility. This is a tremendously important survivorship issue for many people. As an oncologist, I’m often asked questions about preserving fertility during cancer treatment. If this issue affects you, here is an overview of key options. When should you talk to your cancer team about fertility? Future children may not be foremost on your mind when you are diagnosed with cancer. Soon afterward, though, it’s worth talking to your doctor about fertility issues, if this is important to you now or might one day become important. Your doctor can explain: the risk that your cancer might cause infertility the risk that your treatment might cause infertility options before or during treatment that might help you preserve fertility. What might make infertility more likely to occur? When an adult has cancer, some factors that raise risk for infertility include: Age. Infertility is more likely in women who are older at diagnosis. Type of cancer. Some cancers affect fertility, such as Hodgkin’s lymphoma, or prostate cancer in men. Treatments. Some treatments affect fertility by damaging or removing reproductive organs. For example, treating cervical, uterine, or ovarian cancer usually requires removing a woman’s ovaries, fallopian tubes, and uterus. Radiation to the pelvis used to treat colon or uterine cancer can permanently harm ovaries. And some, but not all, chemotherapies needed...
This study aimed to assess the relative safety and short-term efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) and conventional transarterial chemoembolization (c-TACE) for treating peculiar anatomical sites of gastric cancer liver metastasis. MATERIAL AND METHODS Of the 68 patients with gastric cancer liver metastases confirmed by imaging and pathology, 35 were treated with DEB-TACE and 33 with c-TACE. The DEB-TACE group comprised 26 males and 9 females aged 28-75 years (56.8±6.3), and the c-TACE group included 19 males and 14 females aged 33-77 (60.2±9.4) years. Liver functions of th...
CONCLUSIONS The network pharmacology analysis reveals the molecular biological mechanism of Artemisia annua anti-NSCLC via multiple active components, multi-channels, and multi-targets. This suggests that Artemisia annua might be developed as a promising anti-NSCLC drug. PMID: 32474568 [PubMed - in process]
New J. Chem., 2020, Accepted Manuscript DOI: 10.1039/D0NJ01814G, PaperGurpreet Kaur, Monika Chaudhary, Kailash C Jena, Narinder Singh Abstract Environmental contamination due to increase in drug level is touching its alarming stage. There is an array of drugs such as antibiotics, antidepressants, analgesics, cancer chemotherapy drugs etc which... The content of this RSS Feed (c) The Royal Society of Chemistry
Analyst, 2020, Advance Article DOI: 10.1039/D0AN00627K, PaperJun Liu, Cheng Cao We propose a novel GSH-generating prodrug to be used with a sulfonamide-induced “integrative” platform for selective cancer therapy. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Publication date: Available online 31 May 2020Source: Environmental Toxicology and PharmacologyAuthor(s): Badmus O. Olufunto, Njan Anoka, Ologe M. Olufunmilayo, Olatunji A. Lawrence
Research by NIEHS scientists could open the door to improved infertility treatments. (read more)
Hi everyone! I’m looking for advice on which schools to apply to in this cycle. I qualify as Disadvantaged on AMCAS and have FAP so I am able to apply to 20 schools. I’ve left off the Philly schools for personal reasons but am open to any other suggestions for my school list. cGPA: 3.7, sGPA: 3.6 For additional context, I had a really rough first 3 semesters of undergrad which included loss of income for my family, a parent’s cancer diagnosis, and 2 hospitalizations for... WAMC/School List: 3.7 cGPA/3.6 sGPA/515 MCAT
Publication date: Available online 31 May 2020Source: European Journal of RadiologyAuthor(s): Qi Zhang, Han Ouyang, Feng Ye, Shuang Chen, Lizhi Xie, Xinming Zhao, Xiaoduo Yu
CONCLUSIONS: INI seem safe and effective in the prevention of MTCT. Our findings support their use as intensification regimens in pregnant women with high risk of MTCT. PMID: 32473739 [PubMed - as supplied by publisher]
Publication date: Available online 1 June 2020Source: Pregnancy HypertensionAuthor(s): Wenbo Zhou, Guangtong She, Kaiyan Yang, Bin Zhang, Jingbing Liu, Bin Yu
More News: Amenorrhea | Blogging | Breast Cancer | Cancer | Cancer & Oncology | Cancer of the Uterus | Cervical Cancer | Chemotherapy | Children | Colon Cancer | Colorectal Cancer | Endocrinology | Harvard | Health Management | Hormonal Therapy | Hormones | Infertility | Insurance | Learning | Lymphoma | Men | Menopause | Ovarian Cancer | Ovaries | Pregnancy | Pregnancy and Breast Cancer | Prostate Cancer | Reproduction Medicine | Universities & Medical Training | Websites | Women